| 1 |
ClinicalTrials.gov (NCT05756777) A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
|
| 2 |
ClinicalTrials.gov (NCT02677922) A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
|
| 3 |
ClinicalTrials.gov (NCT04955938) A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
|
| 4 |
ClinicalTrials.gov (NCT04092179) Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
|
| 5 |
ClinicalTrials.gov (NCT03383575) Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
|
| 6 |
ClinicalTrials.gov (NCT04281498) Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
|
| 7 |
ClinicalTrials.gov (NCT05401097) IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
|
| 8 |
ClinicalTrials.gov (NCT03839771) A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
|
|
|
|
|
|
|
